To the Editor Trinder and colleagues¹ conclude that LPA genetic risk score and measured lipoprotein(a) level provide comparable risk prediction for incident atherosclerotic cardiovascular disease (ASCVD) and provide improvement in risk discrimination beyond guideline-supported risk scores, which supports that lipoprotein(a) is a risk-enhancing factor.

中文翻译：

---

脂蛋白(a) 用于筛查的临床效用并不能决定脂蛋白(a) 对患者的临床效用

致编辑Trinder 及其同事¹得出结论，LPA遗传风险评分和测得的脂蛋白 (a) 水平为突发动脉粥样硬化性心血管疾病 (ASCVD) 提供了可比的风险预测，并提供了超出指南支持的风险评分的风险识别改进，后者支持脂蛋白 ( a) 是一个风险增强因素。